Morgan Stanley analyst Michael Ulz maintained a Buy rating on Tenaya Therapeutics yesterday and set a price target of $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ulz has given his Buy rating due to a combination of factors related to Tenaya Therapeutics’ innovative approaches in cardiac gene therapy. The company has demonstrated confidence in its methods for assessing protein expression, which is crucial for the development of their gene therapies TN-201 and TN-401. These therapies target specific cardiac conditions, and Tenaya’s use of quantitative mass spectrometry-based proteomic techniques shows promise in understanding and potentially treating these diseases.
Looking forward, Tenaya is set to release important data readouts in the fourth quarter of 2025, focusing on the tolerability and biopsy results of their therapies. This upcoming data is anticipated to provide valuable insights into the effectiveness of their treatments. The management’s strategic focus on protein expression changes over time in patients is a positive indicator of their commitment to advancing their therapeutic programs. Overall, the combination of innovative research methods and the potential for significant data readouts supports the Buy rating.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $5.00 price target.
TNYA’s price has also changed slightly for the past six months – from $1.010 to $1.080, which is a 6.93% increase.